verapamil has been researched along with Alloxan Diabetes in 62 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 8.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "To investigate the efficacy of verapamil eye drops for inhibition of diabetic cataract in rats." | 7.72 | Inhibition of experimental diabetic cataract by topical administration of RS-verapamil hydrochloride. ( Daxer, A; Ettl, A; Göttinger, W; Schmid, E, 2004) |
| "The purpose of the present study was to examine the effects on cataractogenesis of daily sc administration of the Ca2+ antagonist drug verapamil to diabetic rats." | 7.67 | Cataract formation is prevented by administration of verapamil to diabetic rats. ( Afzal, N; Dhalla, NS; Eckhert, CD; Kroeger, EA; Kutryk, MJ; Lockwood, MK; Pierce, GN, 1989) |
| "Preclinical studies were designed to investigate whether the combination of verapamil and trandolapril was more potent than either drug alone for the treatment of hypertension and concomitant cardiovascular or metabolic diseases." | 4.79 | Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. ( Kirchengast, M, 1997) |
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 4.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| "We designed the present study to examine whether diabetes mellitus affects the antiarrhythmic effect of flecainide, a sodium channel blocker, E-4031, a potassium channel blocker, and verapamil, a calcium channel blocker, in diabetic rats." | 3.73 | Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers. ( Hayashi, Y; Ito, I; Iwasaki, M; Kamibayashi, T; Kawai, Y; Mashimo, T; Takada, K; Yamatodani, A, 2006) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "To investigate the efficacy of verapamil eye drops for inhibition of diabetic cataract in rats." | 3.72 | Inhibition of experimental diabetic cataract by topical administration of RS-verapamil hydrochloride. ( Daxer, A; Ettl, A; Göttinger, W; Schmid, E, 2004) |
| "Verapamil poisoning is known to produce hyperglycemia and metabolic acidosis in humans." | 3.69 | The diabetogenic effects of acute verapamil poisoning. ( Kline, JA; Raymond, RM; Schroeder, JD; Watts, JA, 1997) |
| "The purpose of the present study was to examine the effects on cataractogenesis of daily sc administration of the Ca2+ antagonist drug verapamil to diabetic rats." | 3.67 | Cataract formation is prevented by administration of verapamil to diabetic rats. ( Afzal, N; Dhalla, NS; Eckhert, CD; Kroeger, EA; Kutryk, MJ; Lockwood, MK; Pierce, GN, 1989) |
| "Verapamil promotes β-cell IGF-I signaling by increasing phosphorylation of IGF-I receptor and its downstream effector AKT." | 1.91 | Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling. ( Chen, J; Lu, B; Qian, WJ; Sethupathy, P; Shalev, A; Xu, G, 2023) |
| "Verapamil treatment (24, 48 mg/kg/day) significantly affected nano mechanical properties of the femurs, and tended to improve bone microstructures and macro mechanical properties of the femurs, which provided guidance for the selection of verapamil dose in the treatment of type 2 diabetic patients." | 1.72 | Effect of verapamil on bone mass, microstructure and mechanical properties in type 2 diabetes mellitus rats. ( Cen, H; Gong, H; Hu, X; Li, C; Shi, P; Wu, X, 2022) |
| "Verapamil treatment had no significant effect on blood glucose, but blood glucose tended to decline with the increase of verapamil-treated time and dose." | 1.72 | Improved fatigue properties, bone microstructure and blood glucose in type 2 diabetic rats with verapamil treatment. ( Gong, H; Hu, X; Jia, S; Li, J; Wu, X, 2022) |
| "Lung injury has recently been recognized as a consequent complication of diabetes mellitus." | 1.48 | STAT3 and Nrf2 pathways modulate the protective effect of verapamil on lung injury of diabetic rats. ( Hafez, HM; Mohamed, HH; Mohamed, MZ; Zenhom, NM, 2018) |
| " As a result of this, a significant decrease in the intestinal uptake and peroral bioavailability of the P-glycoprotein substrates (verapamil and atorvastatin) was observed along with the progression of diabetes as compared to normal animals." | 1.42 | Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies. ( Agarwal, M; Dash, RP; Ellendula, B; Nivsarkar, M, 2015) |
| " In conclusion, diabetes mellitus revealed a tissue-specific effect on CYP3A activity and expression (induced in liver and inhibited in intestine), resulting in opposite pharmacokinetic behaviors of verapamil after oral and intravenous administration to diabetic rats." | 1.37 | Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. ( Chen, G; Hu, N; Liu, H; Liu, L; Liu, X; Pan, X; Wang, G; Wang, X; Xie, L; Xie, S; Zhang, L, 2011) |
| " Plasma concentrations of verapamil in DM rats, rats fed with HFD, and control (CON) rats were measured after intravenous administration of 1 mg/kg verapamil and corresponding pharmacokinetic parameters were estimated." | 1.37 | Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. ( Chen, GM; Hu, N; Li, J; Liu, L; Liu, XD; Wang, GJ; Wang, P; Xie, L; Xie, SS, 2011) |
| "Verapamil blunted the increase in plasma potassium in diabetic and nondiabetic rats compared with the respective controls." | 1.29 | Effect of verapamil on disposition of intravenous potassium in diabetic anephric uremic rats. ( Blum, M; Cabili, S; Davidovics, Y; Iaina, A; Peer, G; Serban, I; Wollman, Y, 1993) |
| "Nifedipine treatment completely reversed diabetes-induced prolongation in both time-to-peak tension and time-to-90% relaxation." | 1.29 | Influence of calcium channel blocker treatment on the mechanical properties of diabetic rat myocardium. ( Brown, RA; Lee, MM; Savage, AO; Sundareson, AM; Woodbury, DJ, 1996) |
| " Islets from both genetic models showed a left-shifted glucose dose-response curve for insulin release (concentrations for half-maximal release, 5 to 6 mmol/L v 12 to 13 mmol/L in LA/N lean littermates and 3 mmol/L v 10 mmol/L in lean SHR/N)." | 1.28 | Genetically obese rats with (SHR/N-cp) and without diabetes (LA/N-cp) share abnormal islet responses to glucose. ( Recant, L; Timmers, KI; Voyles, NR, 1992) |
| " Calcium induced a concentration dependent increase in dF/dt in normal and diabetic hearts, but in diabetes the dose-response curve to calcium chloride was shifted to the left." | 1.27 | Hypersensitivity to calcium associated with an increased sarcolemmal Ca2+-ATPase activity in diabetic rat heart. ( Borda, E; Pascual, J; Sterin-Borda, L; Wald, M, 1988) |
| "Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree." | 1.27 | Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. ( Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987) |
| "Treatment with enalapril reduced the degree of proteinuria at three months (36." | 1.27 | Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor. ( Jackson, B; Whitty, MR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (17.74) | 18.7374 |
| 1990's | 29 (46.77) | 18.2507 |
| 2000's | 7 (11.29) | 29.6817 |
| 2010's | 11 (17.74) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, N | 2 |
| Xie, S | 1 |
| Liu, L | 2 |
| Wang, X | 1 |
| Pan, X | 1 |
| Chen, G | 1 |
| Zhang, L | 1 |
| Liu, H | 2 |
| Liu, X | 2 |
| Xie, L | 2 |
| Wang, G | 1 |
| Wu, X | 2 |
| Gong, H | 2 |
| Hu, X | 2 |
| Shi, P | 1 |
| Cen, H | 1 |
| Li, C | 1 |
| Jia, S | 1 |
| Li, J | 2 |
| Xu, G | 3 |
| Chen, J | 4 |
| Lu, B | 1 |
| Sethupathy, P | 1 |
| Qian, WJ | 1 |
| Shalev, A | 4 |
| Mohamed, MZ | 1 |
| Hafez, HM | 1 |
| Mohamed, HH | 1 |
| Zenhom, NM | 1 |
| Eissa, LD | 1 |
| Ghobashy, WA | 1 |
| El-Azab, MF | 1 |
| Xu, L | 1 |
| Lin, X | 1 |
| Guan, M | 1 |
| Zeng, Y | 1 |
| Liu, Y | 1 |
| Shan, HL | 1 |
| Wang, Y | 1 |
| Wu, JW | 1 |
| Hang, PZ | 1 |
| Li, X | 1 |
| Sun, LH | 1 |
| Qi, JC | 1 |
| Mao, YY | 1 |
| Sun, ZD | 1 |
| Du, ZM | 1 |
| Li, S | 1 |
| Chen, JD | 1 |
| Dash, RP | 1 |
| Ellendula, B | 1 |
| Agarwal, M | 1 |
| Nivsarkar, M | 1 |
| Cha-Molstad, H | 2 |
| Szabo, A | 1 |
| Satoh, E | 1 |
| Iwasaki, R | 1 |
| Yü, W | 1 |
| Wang, JJ | 1 |
| Wen, ZY | 1 |
| Ouyang, JP | 1 |
| Huang, H | 1 |
| Lin, GS | 1 |
| Huang, CX | 1 |
| Chen, GM | 1 |
| Xie, SS | 1 |
| Wang, P | 1 |
| Wang, GJ | 1 |
| Liu, XD | 1 |
| Jing, G | 2 |
| Young, ME | 1 |
| Chatham, JC | 1 |
| Davis, BJ | 1 |
| Cao, Z | 1 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Ettl, A | 1 |
| Daxer, A | 1 |
| Göttinger, W | 1 |
| Schmid, E | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Ito, I | 1 |
| Hayashi, Y | 1 |
| Kawai, Y | 1 |
| Iwasaki, M | 1 |
| Takada, K | 1 |
| Kamibayashi, T | 1 |
| Yamatodani, A | 1 |
| Mashimo, T | 1 |
| Kametaka, S | 1 |
| Kasahara, T | 1 |
| Ueo, M | 1 |
| Takenaka, M | 1 |
| Saito, M | 1 |
| Sakamoto, K | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| McNeill, JH | 4 |
| Brown, RA | 3 |
| Bhasin, P | 1 |
| Savage, AO | 3 |
| Dunbar, JC | 1 |
| Kim, HR | 1 |
| Rho, HW | 1 |
| Park, BH | 1 |
| Park, JW | 1 |
| Kim, JS | 1 |
| Kim, UH | 1 |
| Chung, MY | 1 |
| Conrad, K | 1 |
| Barbee, RW | 1 |
| Maymind, M | 1 |
| Zimmerman, R | 1 |
| Rodrigues, B | 1 |
| Grassby, PF | 1 |
| Battell, ML | 1 |
| Lee, SY | 1 |
| Davidovics, Y | 1 |
| Peer, G | 1 |
| Cabili, S | 1 |
| Blum, M | 1 |
| Serban, I | 1 |
| Wollman, Y | 1 |
| Iaina, A | 1 |
| Tanaka, Y | 2 |
| Kashiwagi, A | 3 |
| Saeki, Y | 1 |
| Takagi, Y | 2 |
| Asahina, T | 3 |
| Kikkawa, R | 1 |
| Shigeta, Y | 3 |
| Heijnis, JB | 1 |
| van Zwieten, PA | 1 |
| Kaymaz, AA | 1 |
| Tan, H | 1 |
| Altuğ, T | 1 |
| Büyükdevrim, AS | 1 |
| Sundareson, AM | 2 |
| Lee, MM | 2 |
| Woodbury, DJ | 1 |
| Rosenthal, T | 1 |
| Erlich, Y | 1 |
| Rosenmann, E | 1 |
| Cohen, A | 1 |
| Yoo, HJ | 1 |
| Kozaki, K | 1 |
| Akishita, M | 1 |
| Watanabe, M | 1 |
| Eto, M | 1 |
| Nagano, K | 1 |
| Sudo, N | 1 |
| Hashimoto, M | 1 |
| Kim, S | 1 |
| Yoshizumi, M | 1 |
| Toba, K | 1 |
| Ouchi, Y | 1 |
| Kirchengast, M | 1 |
| Kline, JA | 1 |
| Raymond, RM | 1 |
| Schroeder, JD | 1 |
| Watts, JA | 1 |
| Gallego, B | 1 |
| Flores, O | 1 |
| López-Novoa, JM | 1 |
| Pérez-Barriocanal, F | 1 |
| Cekic, O | 1 |
| Bardak, Y | 1 |
| Murat, N | 1 |
| Kalkan, S | 1 |
| Gidener, S | 1 |
| Gordon, EA | 1 |
| Guppy, LJ | 1 |
| Kedziora-Kornatowska, K | 1 |
| Szram, S | 1 |
| Kornatowski, T | 1 |
| Szadujkis-Szadurski, L | 1 |
| Kedziora, J | 1 |
| Bartosz, G | 1 |
| Yu, Z | 2 |
| Lee, SL | 1 |
| Ostadalova, I | 1 |
| Kolar, F | 1 |
| Dhalla, NS | 4 |
| Wong, KK | 1 |
| Tzeng, SF | 1 |
| Timmers, KI | 1 |
| Voyles, NR | 1 |
| Recant, L | 1 |
| Wei, YJ | 1 |
| Yu, GZ | 1 |
| Zhang, GF | 1 |
| Yu, JR | 1 |
| Ogawa, T | 2 |
| Abe, N | 1 |
| Ikebuchi, M | 2 |
| Fein, FS | 1 |
| Zola, BE | 1 |
| Malhotra, A | 1 |
| Cho, S | 1 |
| Factor, SM | 1 |
| Scheuer, J | 1 |
| Sonnenblick, EH | 1 |
| Nishio, Y | 1 |
| Kodama, M | 1 |
| Abebe, W | 1 |
| MacLeod, KM | 1 |
| Borda, E | 2 |
| Pascual, J | 1 |
| Wald, M | 1 |
| Sterin-Borda, L | 1 |
| Jackson, B | 2 |
| Cubela, R | 1 |
| Debrevi, L | 1 |
| Whitty, M | 1 |
| Johnston, CI | 1 |
| Afzal, N | 3 |
| Pierce, GN | 3 |
| Elimban, V | 1 |
| Beamish, RE | 1 |
| Kroeger, EA | 1 |
| Lockwood, MK | 1 |
| Kutryk, MJ | 1 |
| Eckhert, CD | 1 |
| Pieper, GM | 1 |
| Gross, GJ | 1 |
| Whitty, MR | 1 |
| Katsumata, K | 1 |
| Miyao, K | 1 |
| Katsumata, Y | 1 |
| Bank, N | 1 |
| Lahorra, MA | 1 |
| Aynedjian, HS | 1 |
| Ganguly, PK | 1 |
| Dhalla, KS | 1 |
| Singal, PK | 1 |
| Oztürk, Y | 1 |
| Yildizoglu, N | 1 |
| Altan, VM | 1 |
| Karasu, C | 1 |
| Peredo, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for verapamil and Alloxan Diabetes
| Article | Year |
|---|---|
Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Diabet | 1997 |
61 other studies available for verapamil and Alloxan Diabetes
| Article | Year |
|---|---|
Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Calcium Channel Blo | 2011 |
Effect of verapamil on bone mass, microstructure and mechanical properties in type 2 diabetes mellitus rats.
Topics: Animals; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Experimental; Diabetes Mell | 2022 |
Improved fatigue properties, bone microstructure and blood glucose in type 2 diabetic rats with verapamil treatment.
Topics: Animals; Blood Glucose; Bone Density; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fr | 2022 |
Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose; Humans; Insulin-Like G | 2023 |
STAT3 and Nrf2 pathways modulate the protective effect of verapamil on lung injury of diabetic rats.
Topics: Animals; Antioxidants; Cytoprotection; Diabetes Complications; Diabetes Mellitus, Experimental; Lung | 2018 |
Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury.
Topics: Angiogenesis Inhibitors; Animals; Blood Glucose; Calcium Channel Blockers; Cell Cycle Proteins; Diab | 2021 |
Verapamil Attenuated Prediabetic Neuropathy in High-Fat Diet-Fed Mice through Inhibiting TXNIP-Mediated Apoptosis and Inflammation.
Topics: Animals; Anti-Arrhythmia Agents; Apoptosis; Carrier Proteins; Diabetes Mellitus, Experimental; Diet, | 2019 |
Verapamil reverses cardiac iron overload in streptozocin-induced diabetic rats.
Topics: Animals; Anti-Arrhythmia Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Experim | 2013 |
Decreased L-type calcium current in antral smooth muscle cells of STZ-induced diabetic rats.
Topics: Action Potentials; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Diabetes Me | 2014 |
Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availabil | 2015 |
Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein.
Topics: Animals; Apoptosis; Calcium Channel Blockers; Carrier Proteins; Caspase 3; Cell Line; Cell Survival; | 2009 |
Experimental diabetes attenuates calcium mobilization and proliferative response in splenic lymphocytes from mice.
Topics: Animals; Blood Glucose; Body Weight; Calcium; Calcium Channels, L-Type; Concanavalin A; Diabetes Mel | 2011 |
[Influences and mechanism of verapamil on ischemia/reperfusion injury in cardiomyocytes of streptozotocin-induced diabetes mellitus rats].
Topics: Animals; Calcium; Calcium Channels, L-Type; Diabetes Mellitus, Experimental; Male; Myocardial Reperf | 2010 |
Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection.
Topics: Animals; Anti-Arrhythmia Agents; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Diet; Diet | 2011 |
Preventing β-cell loss and diabetes with calcium channel blockers.
Topics: Administration, Oral; Animals; Apoptosis; Calcium Channel Blockers; Carrier Proteins; Cell Line; Dia | 2012 |
Calcium channel blockers act through nuclear factor Y to control transcription of key cardiac genes.
Topics: Acetylation; Animals; Apoptosis; Binding Sites; Calcineurin; Calcium Channel Blockers; Carrier Prote | 2012 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
Inhibition of experimental diabetic cataract by topical administration of RS-verapamil hydrochloride.
Topics: Animals; Calcium Channel Blockers; Cataract; Diabetes Mellitus, Experimental; Disease Progression; I | 2004 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Diabetes Mellitus; Diabetes M | 2006 |
Effect of nifedipine on severe experimental cataract in diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Cataract; Diabetes Me | 2008 |
Effects of vanadium treatment on the alterations of cardiac glycogen phosphorylase and phosphorylase kinase in streptozotocin-induced chronic diabetic rats.
Topics: Animals; Cyclic AMP; Diabetes Mellitus, Experimental; Male; Myocardium; Phosphorylase Kinase; Phosph | 1994 |
Chronic verapamil treatment attenuates the negative inotropic effect of ethanol in diabetic rat myocardium.
Topics: Animals; Cardiomyopathy, Dilated; Diabetes Mellitus, Experimental; Drug Interactions; Ethanol; Male; | 1994 |
Role of Ca2+ in alloxan-induced pancreatic beta-cell damage.
Topics: Animals; Blood Glucose; Calcium; Diabetes Mellitus, Experimental; Hydrogen Peroxide; Insulin; Islets | 1994 |
Effect of verapamil and captopril on endothelial injury in the diabetic hypertensive rat.
Topics: Animals; Blood Pressure; Blood Vessels; Body Weight; Captopril; Diabetes Mellitus, Experimental; End | 1994 |
Hypertriglyceridemia in experimental diabetes: relationship to cardiac dysfunction.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Cholesterol; Clofibrate; Diabetes Mellitus, Experim | 1994 |
Effect of verapamil on disposition of intravenous potassium in diabetic anephric uremic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Nephrectomy; Potassium; Potassium Chloride; Rats; Rats, Sp | 1993 |
Effects of verapamil on the cardiac alpha 1-adrenoceptor signalling system in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Heart; Inosine Triphosphate; I | 1993 |
Effects of calcium antagonists on K(+)-induced contraction in isolated aorta from diabetic and age-matched control rats.
Topics: Animals; Aorta, Thoracic; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diltiazem; In V | 1993 |
The effects of calcium channel blockers, verapamil, nifedipine and diltiazem, on metabolic control in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Ex | 1995 |
Differential effects of chronic calcium channel blocker treatment on the inotropic response of diabetic rat myocardium to acute ethanol exposure.
Topics: Animals; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Drug Antagonism; Ethanol; Male; | 1996 |
Influence of calcium channel blocker treatment on the mechanical properties of diabetic rat myocardium.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Calcium Channel Blockers; Diabetes Mellit | 1996 |
Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose | 1997 |
Augmented Ca2+ influx is involved in the mechanism of enhanced proliferation of cultured vascular smooth muscle cells from spontaneously diabetic Goto-Kakizaki rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1997 |
The diabetogenic effects of acute verapamil poisoning.
Topics: Animals; Diabetes Mellitus, Experimental; Dogs; Female; Glucagon; Glucose; Hyperglycemia; Infusions, | 1997 |
Renal effects of antihypertensive therapy in uninephrectomized diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus, Exper | 1997 |
Lenticular calcium, magnesium, and iron levels in diabetic rats and verapamil effect.
Topics: Animals; Blood Glucose; Calcium; Calcium Channel Blockers; Cataract; Diabetes Mellitus, Experimental | 1998 |
Effect of verapamil on responses to endothelin-1 in aortic rings from streptozotocin-induced diabetic rats.
Topics: Animals; Aorta, Thoracic; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothe | 1999 |
Cardiomyopathic changes in streptozotocin-induced diabetes.
Topics: Adenosine Triphosphatases; Animals; Body Weight; Calcium Channel Blockers; Cardiomyopathies; Cardiot | 1999 |
The effect of verapamil on the antioxidant defence system in diabetic kidney.
Topics: Albuminuria; Animals; Antioxidants; Basement Membrane; Blood Glucose; Body Weight; Catalase; Diabete | 2002 |
Blood pressure and heart rate response to vasoactive agents in conscious diabetic rats.
Topics: Acetylcholine; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Heart Rate; Hydralazine; Is | 1992 |
Alterations in Ca(2+)-channels during the development of diabetic cardiomyopathy.
Topics: Animals; Blood Glucose; Brain; Calcium; Calcium Channels; Calcium-Transporting ATPases; Cardiomyopat | 1992 |
Norepinephrine-induced contractile responses in isolated rat aortae from different duration of diabetes.
Topics: Animals; Aorta, Thoracic; Bethanechol; Bethanechol Compounds; Diabetes Mellitus, Experimental; Dose- | 1992 |
Genetically obese rats with (SHR/N-cp) and without diabetes (LA/N-cp) share abnormal islet responses to glucose.
Topics: Animals; Blood Glucose; Blotting, Western; Cell Separation; Cells, Cultured; Diabetes Mellitus, Expe | 1992 |
[Protective effect of verapamil against alloxan-induced damage on pancreatic islet beta-cells in rats].
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Islets of | 1992 |
Altered inotropic responses in diabetic cardiomyopathy and hypertensive-diabetic cardiomyopathy.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1991 |
Effect of verapamil on cardiac protein kinase C activity in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Heart Ventricles; Insulin; Mal | 1991 |
Hypertensive-diabetic cardiomyopathy in rats.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Cardiomyopathies; Contractile Proteins; Diab | 1990 |
Increase in [3H]PN 200-110 binding to cardiac muscle membrane in streptozocin-induced diabetic rats.
Topics: Animals; Binding Sites; Blood Glucose; Calcium; Diabetes Mellitus, Experimental; In Vitro Techniques | 1990 |
Protein kinase C-mediated contractile responses of arteries from diabetic rats.
Topics: Alkaloids; Animals; Aorta, Thoracic; Blood Glucose; Calcium; Diabetes Mellitus, Experimental; In Vit | 1990 |
Hypersensitivity to calcium associated with an increased sarcolemmal Ca2+-ATPase activity in diabetic rat heart.
Topics: Animals; Calcium; Calcium-Transporting ATPases; Diabetes Mellitus, Experimental; Dose-Response Relat | 1988 |
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Diabetes Mellitus, Expe | 1987 |
Influence of verapamil on some subcellular defects in diabetic cardiomyopathy.
Topics: Adenosine Triphosphatases; Animals; Biological Transport; Calcium; Calcium-Transporting ATPases; Car | 1989 |
Cataract formation is prevented by administration of verapamil to diabetic rats.
Topics: Animals; Calcium; Cataract; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diltiazem; Inject | 1989 |
Diabetes enhances vasoreactivity to calcium entry blockers.
Topics: Animals; Aorta, Thoracic; Diabetes Mellitus, Experimental; Diltiazem; Heart; In Vitro Techniques; Ma | 1989 |
Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; | 1988 |
Verapamil induces protection of alloxan but not streptozotocin-induced diabetes in rats.
Topics: Alloxan; Animals; Diabetes Mellitus, Experimental; Male; Rats; Rats, Inbred Strains; Streptozocin; V | 1988 |
Acute effect of calcium and insulin on hyperfiltration of early diabetes.
Topics: Animals; Bicarbonates; Blood Pressure; Calcium; Carbon Dioxide; Diabetes Mellitus, Experimental; Dia | 1987 |
Beneficial effects of verapamil in diabetic cardiomyopathy.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Calcium; Cardiomyop | 1988 |
Altered responses to calcium and trifluoperazine in K+-depolarized duodenum from alloxan diabetic rats.
Topics: Animals; Calcium; Diabetes Mellitus, Experimental; Duodenum; Guinea Pigs; Male; Muscle, Smooth; Neur | 1987 |
The effects of norepinephrine and acetylcholine in the vas deferens from normal and diabetic rats: influence of ouabain and verapamil.
Topics: Acetylcholine; Animals; Diabetes Mellitus, Experimental; In Vitro Techniques; Male; Muscle Contracti | 1985 |